

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: BioHarvest Sciences Inc. (the "Issuer").

Trading Symbol: BHSC

Number of Outstanding Listed Securities: 439,719,501

Date: October 7, 2020

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non- promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On September 8th, 2020, the Issuer announced a private placement offering of up to 25,428,055 common shares at a price of \$0.15 per share for total proceeds of up to \$3,814,208.25, with the issuance of 5% finder's warrants exercisable at \$0.15 per share for a period of 1 year and/or up to 5% finder's cash commission to finders where permitted by law. The issuer plans to use the funds to accelerate its VINIA® marketing program, to invest in the required Capital Equipment for its new 20 Ton BioFarming manufacturing facility, and for general corporate purposes.

The Issuer entered into an Agreement on September 10, 2020, with Total Sweeteners Inc. DBA Batory Foods ("Batory"). Under the terms of the Agreement, Batory was granted the exclusive distributor rights for the Issuer's products to food and beverage producers in the United States including the Issuer's food based products and proposed hemp based CBD products.

On September 14th, 2020, the Issuer closed the first tranche of its private placement consisting of 21,492,221 common shares at a price of \$0.15 per share for aggregate gross proceeds of \$3,223,833.15. \$115,848 Finder's cash commission and 680,545 finder's warrants were issued.

FORM 7 – MONTHLY PROGRESS REPORT

January 2015

Page 1

On September 16th, 2020, the Issuer held a Zoom Live Conference to update its shareholders and the general public on its Growth Strategy progress, revealed the launch of its new bioharvest.com website and new B2C Marketing website in Israel. In addition shareholders were updated on the progress made in the building of a 20 Ton facility with Sugart Israel, estimated to be operational in early Q3, 2021.

2. Provide a general overview and discussion of the activities of management.

Management focused on executing the Company growth strategy.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not Applicable

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not Applicable

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On September 9th, 2020 the Issuer entered into an Investor Relations Agreement with Justin Meiklem for a monthly fee of \$10,000. The agreement may be terminated by the Issuer on 30 days-notice. The Issuer agreed to issue the Consultant non-transferable share purchase warrants for the purchase of up to 300,000 shares of the Company at an exercise price of \$0.15 per warrant, exercisable for a period of 18 months from issuance.

The Issuer entered into an agreement with Total Sweeteners Inc. DBA Batory Foods as detailed in #1 above.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not Applicable

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not Applicable

8. Describe the acquisition of new customers or loss of customers.

Not Applicable

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

Not Applicable

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not Applicable

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not Applicable

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not Applicable

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not Applicable

14. Provide details of any securities issued and options or warrants granted.

On September 10th, 2020, the Issuer announced the grant of 700,000 incentive stock options to Officer and Directors, vesting quarterly over a 2-year period and exercisable at \$0.15 per unit for a term of 10 years. Out of the 700,000 incentive stock options granted, only 550,000 were issued by the issuer. Upon review by the Issuer, the remaining 150,000 incentive stock options will not be issued.

On September 14th, 2020, the Issuer closed the first tranche of its private placement consisting of 21,492,221 common shares at a price of \$0.15 per share for aggregate gross proceeds of \$3,223,833.15. \$115,848 Finder's cash commission and 680,545 finder's warrants were issued.

15. Provide details of any loans to or by Related Persons.

Not Applicable

16. Provide details of any changes in directors, officers or committee members.

Not Applicable

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Issuer has been impacted by the emerging and ongoing COVID-19 pandemic which is impacting the efficient running of its operations. All efforts are being taken by the Issuer to minimize the impact across the business operations and the Issuer will be in a better position to assess any potential impact on timelines and sales estimates at the end of Q4.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated October 7, 2020

David Ryan
Name of Director or Senior Officer

"David Ryan"
Signature

Vice-President of IR
Official Capacity

Issuer Details		For Month Ended	Date of Report YY/MM/DD
Name of Issuer BioHarvest Sciences Inc.		September 2020	20/10/07
Issuer Address 1140 - 625 Howe Street			
City/Province/Postal Code Vancouver, BC, V6C 2T6		Issuer Fax No. ()	Issuer Telephone No. (604) 622-1186
Contact Name David Ryan		Contact Position VP of Investor Relations	Contact Telephone No. (604) 622-1186
Contact Email Address: dave@bioharvest.com		Web Site Address www.bioharvest.com	